Article

Ixazomib/Daratumumab Elicits Encouraging Response in Elderly Frail Patients With R/R Multiple Myeloma

Author(s):

Ixazomib plus daratumumab without dexamethasone showed a positive efficacy profile for elderly frail patients with relapsed/refractory multiple myeloma, according to results of the phase 2 IFM 2018-02 study.

Ixazomib (Ninlaro) plus daratumumab (Darzalex) without dexamethasone showed a positive efficacy profile for elderly frail patients with relapsed/refractory multiple myeloma, according to results of the phase 2 IFM 2018-02 study (NCT03757221) presented at the 2022 ASCO Annual Meeting.1

Investigators enrolled patients aged 65 years or older with relapsed or refractory multiple myeloma after 1 or 2 prior lines of therapy who have an International Myeloma Working Group frailty score of 2 or more.

Among all evaluable patients, the overall response rate (ORR) was 76%, with 34% of patients having a very good partial response (VGPR) or better. In lenalidomide (Revlimid) refractory patients, the ORR was 71% and the VGPR or better rate was 41%. In those with high-risk cytogenetics, the ORR was 87% and the VGPR or better rate was 60%.

“Early toxicity remains a concern in elderly frail patients. [Subcutaneous] daratumumab will further reduce infusion-related reactions and facilitate treatment management. [Additionally], in elderly frail patients with newly diagnosed multiple myeloma, [Intergroupe Francophone du Myelome] is currently evaluating lenalidomide plus daratumumab without dexamethasone in the phase 3 study IFM 2017-03,” Cyrille Touzeau, MD, PhD, of University Hospital Hôtel-Dieu in Nantes, France.

Results of the study were previously presented at the 63rd Annual American Society of Hematology Annual Meeting and Exposition, at which time 24% of patients overall achieved a VGPR or better and those who were refractory to lenalidomide had a VGPR or better response rate of 38%. Investigators noted that the response rates were in accordance with those observed in a phase 2 trial (NCT03439293) of ixazomib and daratumumab with dexamethasone.2

A total of 55 patients were enrolled to received intravenous daratumumab at 16 mg/kg on days 1, 8, 15, and 22 in cycles 1 and 2; days 1 and 15 in cycles 3 to 6; and day 1 in cycle 7 and beyond. Patients also received oral ixazomib at 4 mg on days 1, 8, and 15 during all cycles.

Patients must have been naïve to daratumumab and ixazomib therapy, had an ECOG performance score of 0 to 2, and had adequate bone marrow and organ function. The primary end point was VGPR rate, and the secondary end points were safety, ORR, progression-free survival (PFS), overall survival (OS), time to progression, and time to response.

Patient characteristics included a median age of 82 years (range, 72-93), with 76% of patients having a frailty score of 2 or more, and the rest had a score of 3 or 4. At diagnosis, 41 patients were evaluated for the International Staging System stage, with 27% having stage 1, 44% having stage 2, and 29% had stage 3 disease. Most patients (65%) had 1 prior line of therapy. Forty-seven patients were evaluated for high-risk cytogenetics, with 19% having 17p deletion, 17% having t(4:14), and 1 with both. Additionally, 36% of patients were lenalidomide refractory, and 60% were bortezomib refractory.

At the median follow-up of 15.2 months, the estimated PFS rate at 1 year was 70% and the estimated OS rate was 87%.

At the data cutoff of May 11, 2022, 40% of patients were still receiving therapy with a median duration of treatment of 13 months. Additionally, 60% of patients discontinued treatment due to either progressive disease (38%), adverse effects (5.4%), withdrawal from the study (3.5%), or death (11%). Median treatment duration in those who discontinued therapy was 8 months.

Grade 3 or higher AEs included thrombocytopenia (16%), infection (14%), other cytopenias (7%), hypertension (5%), gastrointestinal disorder (5%), diarrhea (4%), daratumumab infusion-related reaction (4%), and nausea or vomiting (2%). A total of 9 patients (16%) died, 2 of which were treatment-related from 1 causes each of daratumumab-related bronchospasm or ixazomib overdose. Other causes of death included disease progression in 7%, and infection in 5%.

Of note, daratumumab plus ixazomib are approved across various indications for patients with multiple myeloma.

References

  1. Marco M, Parienti JJ, Mariette C, et al. Ixazomib and daratumumab without dexamethasone (I-Dara) in elderly frail RRMM patients: a multicenter phase 2 study (IFM 2018-02) of the Intergroupe Francophone du Myélome (IFM). J Clin Oncol. 2022;40 (suppl 16):8000. doi:10.1200/JCO.2022.40.16_suppl.8000
  2. Orlowski RT, Delimpasi S, Straub J, et al. Efficacy and safety of oral ixazomib (Ixa), intravenous (IV) daratumumab (Dara), and IV/oral dexamethasone (dex; IDd) in relapsed/refractory multiple myeloma (RRMM) patients (pts) with 1–3 prior therapies: results of the second interim analysis (IA2) of a phase 2 study. Blood. 2021;138(suppl 1):1666.

Related Videos
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Douglas W. Sborov, MD, MS
Meletios (Thanos) Dimopoulos, MD, professor, therapeutics, Hematology Oncology, National and Kapodistrian University of Athens School of Medicine
Michel Delforge, MD, PhD
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec